Selection of cytotoxicity markers for the screening of new chemical entities in a pharmaceutical con.docx
- 文档编号:2383411
- 上传时间:2022-10-29
- 格式:DOCX
- 页数:12
- 大小:56.98KB
Selection of cytotoxicity markers for the screening of new chemical entities in a pharmaceutical con.docx
《Selection of cytotoxicity markers for the screening of new chemical entities in a pharmaceutical con.docx》由会员分享,可在线阅读,更多相关《Selection of cytotoxicity markers for the screening of new chemical entities in a pharmaceutical con.docx(12页珍藏版)》请在冰豆网上搜索。
Selectionofcytotoxicitymarkersforthescreeningofnewchemicalentitiesinapharmaceuticalcon
Detailedreviewoftransgenicrodentmutationassays ReviewArticle
MutationResearch/ReviewsinMutationResearch
Tissuecollectionindrugdiscoveryanddevelopmentresearch OriginalResearchArticle
EuropeanJournalofCancerSupplements
majorstepintargetedcancerdrugdiscoveryisdemonstrating‘proofofmechanism’.Tissuesamplesareanintegralpartofcurrentdrugdevelopment.AttheBiotherapyDevelopmentAssociationMeetinginMarch2007,thebenefitsandproblemsoftissuerelatedendpointinclusioninclinicaldrugdevelopmentwerediscussed;Academic,RegulatoryAuthorityandPharmaceuticalIndustryrepresentationbeingpresent.
Itwasagreedthatthepublicsupportstheuseofhumantissueinresearch;cooperationandcollaborationareessentialtoensurethattissuesamplesarecollectedandavailableforresearch;tissuesamplingshouldbemandatoryforclinicaltrials;andthattissueremainingfromdiagnostic,surgicalandclinicaltrialbasedsamplingshouldbemadeavailableforresearch.
Untilexistingornewtechnologiesprovideutilityforalternativesampling,accesstohumantissuesamplesofconsistentqualitywillunderpinthesuccessofcancerdrugpipelinesintheeraofmolecularbiologicalbiomarkersandpersonalisedmedicine.
ArticleOutline
1.Introduction
2.Baseline
3.Definitions
4.Infrastructureandcoordination
5.Tissuebanks
5.1.Benefitsofperformingbiopsiesinoncologyclinicaltrials
5.2.Issueswithperformingbiopsiesinoncologyclinicaltrials
6.Conclusion
Conflictofintereststatement
References
Thefutureofdrugdiscoveryanddevelopment:
Shiftingemphasistowardspersonalizedmedicine OriginalResearchArticle
TechnologicalForecastingandSocialChange
Thedrugdiscoverysectorisbeingrevolutionizedbythecurrentrateofadvancesinthepublicandprivatehumangenomeprojectsandbythedevelopmentofnewtechnologiesforbiomarkertesting.Ineffect,asthegeneticrootsofdisease,diseaseprogressionandtreatmenteffectivenessareuncovered,thedemandforsophisticatedprognostic,diagnosticandmonitoringtestswillbeincreasing.Alreadythishasledtothedevelopmentofinnovativediagnosticsproductsmeetingthecriteriaofimprovedefficacyandsafetyaswellasbettercost-benefits.Inordertoachievetheultimategoalofamorepredictiveandpersonalizedmedicinerequiresthedrugdiscoveryindustrytoimplementmoresynergiesbetweenthetwoworldsofclinicalresearchanddiagnostics.Thetherapeuticsthatareenabledbythatstrategyareoftencalled“theranostics”—highlyspecificteststhatallowforthediagnosisofthedisease,buttoadministerthemostappropriatetreatmentregimen,andtomonitorapatient'sresponsetotherapy.Biomarkerswillconstituteacriticalcomponentofthehealthcaredeliverysysteminordertodetect,diagnoseandmonitordiseasesandothermedicalconditionsaswellastoevaluatetreatmentoptionsandeffectiveness.Whilediagnosticbreakthroughstypicallyprecedetherapeuticadvances,thepresenceofnewtherapiescanstimulatethedemandfortesting.Themainquestionthatremainstobeansweredishowwillthebiomarkerparadigmaltersthesecompanies'innovationandcommercializationstrategies.Whereasdevelopingdrugtargetsmayoffergreaterlong-termvalue,initialcommercialopportunitiesoftenariseindiagnostics.
ArticleOutline
1.Introduction
2.Introductiontobiomarkers
3.Drugdiscoveryindustry:
Benefitsfrombiomarkerutilization
3.1.Diseaseunderstanding
3.2.Projectprioritizationthroughearlyattrition
3.3.Streamliningclinicaltrials
3.4.Reducingcostofdrugdevelopment
3.5.Speedingdrugdevelopment
3.6.Improveddecisionmaking
3.7.Avoidingadversedrugreactions(ADR)
3.8.Rationalizingdosingregimen
3.9.Drugrepositioning
4.Factorsinfluencingdevelopmentstrategiestoembracebiomarkers
4.1.Favourableregulatorycontext
4.2.Successinclinicallaboratory
4.2.1.Cancer
4.2.2.Infectiousdiseases
4.2.3.Pharmacogenomics
4.3.Technologicalchallengesremain
4.4.Complexity
4.5.Thequestforvalueremainstobedetermined
4.6.Nodominantdevelopmentmodelhasyetemerged
5.Theimpactofthefinancialcrisis
6.Concludingremarks
References
Vitae
Applicationoftoxicogenomictoolsinthedrugresearchanddevelopmentprocess OriginalResearchArticle
ToxicologyLetters
Drug-resistanttuberculosisintheEuropeanUnion:
Opportunitiesandchallengesforcontrol ReviewArticle
Tuberculosis
Mathematicalmodellingandquantitativemethods ReviewArticle
FoodandChemicalToxicology
CurrentregulatorytoxicologyperspectivesonthedevelopmentofherbalmedicinestoprescriptiondrugproductsintheUnitedStates ReviewArticle
FoodandChemicalToxicology
Toxicologicalstudiesc
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- Selection of cytotoxicity markers for the screening new chemical entities in pharmaceutical con
链接地址:https://www.bdocx.com/doc/2383411.html